Search Results - "Andrius Zucenka"

Refine Results
  1. 1
  2. 2
  3. 3

    The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies by Daraskevicius, Justinas, Petraitis, Vidmantas, Davainis, Linas, Zucenka, Andrius

    Published in Journal of fungi (Basel) (23-04-2022)
    “…Invasive fungal diseases (IFD) remain a major cause of morbidity and mortality in hematological patients, especially those undergoing hematopoietic stem cell…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia by Zucenka, Andrius, Griskevicius, Laimonas

    Published in British journal of haematology (01-04-2024)
    “…We have conducted a retrospective, single-centre analysis of 20 patients with relapsed or refractory FLT3-mutated acute myeloid leukaemia (FLT3m AML) who…”
    Get full text
    Journal Article
  6. 6

    A Case of Successful Allogeneic Hematopoietic Stem Cell Transplantation in a Severely Underweight Patient with Aplastic Anemia by Banceviča, Lilija, Žučenka, Andrius

    Published in Case reports in hematology (04-03-2024)
    “…Allogeneic hematopoietic stem cell transplantation (alloHSTC) is considered definitive and the most effective treatment for young patients diagnosed with…”
    Get full text
    Journal Article
  7. 7

    Case report: Relapsed/refractory extranodal natural killer/T-cell lymphoma nasal type with extensive central nervous system involvement by Dapkevičiūtė-Purlienė, Austėja, Augustinavičius, Vytautas, Žučenka, Andrius

    Published in Pathology oncology research (09-01-2023)
    “…Extranodal natural killer/T-cell lymphoma (ENKL) is a rare subtype of mature T and natural killer cell lymphomas associated with Epstein-Barr virus. A…”
    Get full text
    Journal Article
  8. 8

    Oxidative phosphorylation inhibition induces anticancerous changes in therapy‐resistant–acute myeloid leukemia patient cells by Vitkevičienė, Aida, Janulis, Vytautas, Žučenka, Andrius, Borutinskaitė, Veronika, Kaupinis, Algirdas, Valius, Mindaugas, Griškevičius, Laimonas, Navakauskienė, Rūta

    Published in Molecular carcinogenesis (01-11-2019)
    “…Treatment of acute myeloid leukemia (AML) is still a challenge because of common relapses or resistance to treatment. Therefore, the development of new…”
    Get full text
    Journal Article
  9. 9

    Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation by Čepulytė, Rūta, Pečeliūnas, Valdas, Žučenka, Andrius

    Published in Case reports in hematology (15-10-2020)
    “…Multiple myeloma (MM) is an incurable plasma cell neoplasia characterized by relapsed and/or refractory (R/R) disease course, which poses a major therapeutic…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission by Borutinskaitė, Veronika, Žučenka, Andrius, Vitkevičienė, Aida, Stoškus, Mindaugas, Kaupinis, Algirdas, Valius, Mindaugas, Gineikienė, Eglė, Navakauskienė, Rūta

    Published in Frontiers in genetics (12-04-2022)
    “…Acute myeloid leukemia (AML) is an aggressive, heterogeneous group of malignancies with different clinical behaviors and different responses to therapy. For…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Outcomes and Risk Factors of Critically Ill Patients with Hematological Malignancy. Prospective Single-Centre Observational Study by Judickas, Šarūnas, Stasiūnaitis, Raimundas, Žučenka, Andrius, Žvirblis, Tadas, Šerpytis, Mindaugas, Šipylaitė, Jūratė

    Published in Medicina (Kaunas, Lithuania) (30-11-2021)
    “…: Oncohematological patients have a high risk of mortality when they need treatment in an intensive care unit (ICU). The aim of our study is to analyze the…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16

    Venetoclax, Actinomycin D and Low Dose Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia in Clinical Practice Setting by Zucenka, Andrius, Vaitekėnaitė, Vilmantė, Maneikis, Kazimieras, Pileckytė, Regina, Trociukas, Igoris, Pečeliūnas, Valdas, Griškevičius, Laimonas

    Published in Blood (23-11-2021)
    “…Background Venetoclax based therapies have produced varying results in the relapsed or refractory acute myeloid leukemia (R/R AML) setting. Highest response…”
    Get full text
    Journal Article
  17. 17

    Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant by Zucenka, Andrius, Issa, Ghayas C., Arellano, Martha, Khazal, Sajad, Khera, Nandita, Stock, Wendy, Cuglievan, Branko, Gu, Yu, Nguyen, Huy Van, Smith, Angela R., Stein, Eytan M.

    Published in Blood (02-11-2023)
    “…Background: The potent and selective oral menin-histone-lysine N-methyltransferase 2A (KMT2A) inhibitor revumenib (SNDX-5613) induced complete remissions with…”
    Get full text
    Journal Article
  18. 18

    HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia by Navakauskiene, Ruta, Borutinskaitė, Veronika, Gineikienė, Eglė, Stoškus, Mindaugas, Žučenka, Andrius, Skiauterytė, Giedrė, Vitkevičienė, Aida, Griškevičius, Laimonas

    Published in Journal of oncology (2019)
    “…Acute promyelocytic leukemia (APL) is characterized by PML-RARA translocation, which causes the blockage of promyelocyte differentiation. Conventional…”
    Get full text
    Journal Article
  19. 19
  20. 20